For what it is worth, a little bird told me that, at the beginning of November, Calimmune was halfway through dosing its second cohort (2 out of 4 patients) and is on track for cohort three to start dosing early in the New Year. If this is true, then we should be looking at some results Q3 2015.
For what it is worth, a little bird told me that, at the...
Add to My Watchlist
What is My Watchlist?